Mutsaers A J, Mohammed S I, DeNicola D B, Snyder P W, Glickman N W, Bennett P F, de Gortari A E, Bonney P L, Knapp D W
Department of Veterinary Clinical Sciences, Purdue University, Lynn Hall of Veterinary Medicine, 625 Harrison St., West Lafayette, IN 47907-2026, USA.
Prostaglandins Leukot Essent Fatty Acids. 2005 Mar;72(3):181-6. doi: 10.1016/j.plefa.2004.10.017.
The purpose of this study was to determine the extent to which pretreatment prostaglandin E2 (PGE2) concentration and cyclooxygenase-2 (cox-2) expression could be used to predict the antitumor activity of cox inhibitor treatment in naturally occurring canine transitional cell carcinoma of the urinary bladder (TCC). Snap frozen tissues (to measure PGE2) and formalin-fixed TCC samples (for cox-2 immunohistochemistry) were obtained by cystoscopy or surgery. Complete tumor staging was performed before and after one month of treatment with the cox inhibitor, piroxicam (0.3 mg/kg q24 h po). The pretreatment PGE2 concentration ranged from 57 to 1624 ng/g of TCC tissue; n=18 dogs). Cox-2 immunoreactivity was observed in all TCC samples. There was no association between PGE2 concentration, cox-2 expression, and change in tumor volume with piroxicam treatment. In conclusion, cox-2 expression or PGE2 concentration alone, or the combination of the two was not useful in predicting response to piroxicam treatment in canine TCC.
本研究的目的是确定治疗前前列腺素E2（PGE2）浓度和环氧化酶-2（COX-2）表达可用于预测环氧化酶抑制剂治疗自然发生的犬膀胱移行细胞癌（TCC）抗肿瘤活性的程度。通过膀胱镜检查或手术获取速冻组织（用于测量PGE2）和福尔马林固定的TCC样本（用于COX-2免疫组织化学）。在用环氧化酶抑制剂吡罗昔康（0.3mg/kg，每24小时口服一次）治疗一个月前后进行完整的肿瘤分期。治疗前PGE2浓度范围为57至1624ng/g TCC组织；n = 18只犬）。在所有TCC样本中均观察到COX-2免疫反应性。PGE2浓度、COX-2表达与吡罗昔康治疗后肿瘤体积变化之间无关联。总之，单独的COX-2表达或PGE2浓度，或两者的组合在预测犬TCC对吡罗昔康治疗的反应方面均无用处。
